Boerhinger Ingelheim grows cancer care product line by buying NBE Therapeutics
Boerhinger Ingelheim grows cancer care product line by buying NBE Therapeutics
… Boerhinger Ingelheim buys oncology therapy innovator NBE Therapeutics …

Boehringer Ingelheim Acquiring NBE Therapeutics For $1.5 Billion

NBE Therapeutics’ novel oncology clinical technology is sought by Boehringer Ingelheim to boost new cancer drug development pipeline

John G. Baresky

  • $257 million for Vira Therapeutics (oncolytic cancer-destroying viruses and specifically its proprietary oncolytic virus, VSV-GP) in 2018

NBE product pipeline details

NBE’s leading candidate is NBE-002 (a monoclonal antibody “mAb”) that is being developed as a potential treatment for triple-negative breast cancer (TNBC) plus lung and/or ovarian cancer. Another candidate in NBE’s product development lineup, NBE-105, is intended for the treatment of solid tumors.

  • SOTIO, an immunotherapy biotechnology company headquartered in Prague, Czech Republic

Boehringer seeks to build out its oncology business unit

Through partnering with Exelixis and SOTIO plus buying NBE Therapeutics (which is also privately held) and acquiring AMAL and Vira, Boehringer is amplifying its plans to build up its line of cancer treatment therapies. Their oncology research strategy focuses primarily on two approaches:

  • Immune cell-directed therapies.

A global competitor in multiple biotech and pharmaceutical market sectors

Boehringer Ingelheim is based in Ingelheim am Rhein, Germany; its U.S. headquarters is located in Ridgefield, Connecticut. Founded in 1885, it produced over $23 billion in annual sales during 2019. Their present portfolio of pharmaceutical products spans several competitive categories including:

  • Central Nervous System (CNS)
  • Immunology
  • Metabolic
  • Oncology
  • Respiratory
  • Retinal
  • Biopharmaceutical contract manufacturing

2020 has been a busy year for companies doing business in cancer care

Oncology-related deals are plentiful in the healthcare industry this year. These and other large-scale business maneuvers have taken place so companies can accelerate their cancer treatment research & development capabilities and improve their competitive position with new, advanced products:

Licensing and merger & acquisition deals are pivotal strategies of pharma and diagnostic companies competing in oncology

Mid to large-sized biotech and pharmaceutical manufacturers as well as diagnostic companies maintain their own internal research & development programs in oncology. They supplement them through licensing and acquisition deals with smaller firms that develop new product candidates.

Written by

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store